IA
CHRS icon

IFP Advisors’s Coherus Oncology CHRS Stock Holding History

IFP Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$734 Sell
524
-86
-14% -$140 ﹤0.01% 4596
2026
Q1 		$1.03K Sell
610
-68
-10% -$121 ﹤0.01% 4209
2025
Q4 		$963 Buy
678
+291
+75% +$424 ﹤0.01% 4085
2025
Q3 		$635 Buy
387
+10
+3% +$11 ﹤0.01% 4103
2025
Q2 		$276 Buy
377
+153
+68% +$132 ﹤0.01% 4572
2025
Q1 		$181 Hold
224
– – ﹤0.01% 3693
2024
Q4 		$309 Buy
+224
New +$251 ﹤0.01% 3560
2023
Q1 		– Sell
-1,000
Closed -$16K – 3540
2022
Q4 		$16K Buy
+1,000
New +$7.69K ﹤0.01% 3057
2022
Q1 		– Sell
-53
Closed -$1K – 4550
2021
Q4 		$1K Buy
+53
New +$927 ﹤0.01% 2959
2021
Q1 		– Sell
-18
Closed -$306 – 3027
2020
Q4 		$0 Sell
18
-17
-49% -$303 ﹤0.01% 2959
2020
Q3 		$0 Buy
+35
New +$651 ﹤0.01% 2852
2020
Q2 		– Sell
-161
Closed -$2.73K – 2757
2020
Q1 		$3K Buy
161
+21
+15% +$388 ﹤0.01% 2232
2019
Q4 		$3K Hold
140
– – ﹤0.01% 2352
2019
Q3 		$3K Buy
+140
New +$2.8K ﹤0.01% 2517

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

IFP Advisors's CHRS Position: Q2 2026 in Review

IFP Advisors reduced its Coherus Oncology (CHRS) stake by 14% in Q2 2026, selling an estimated $140 and leaving 524 shares worth $734. The position accounts for ﹤0.01% of the portfolio, ranked #4596.

IFP Advisors first reported a position in CHRS in Q3 2019 and has held it in 14 quarters since. The position peaked at $16K in Q4 2022. 146 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • IFP Advisors held 524 shares of Coherus Oncology worth $734 as of Q2 2026.
  • IFP Advisors sold 86 Coherus Oncology shares in Q2 2026, an estimated $140.
  • Coherus Oncology made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #4596 holding.
  • IFP Advisors first reported a position in Coherus Oncology in Q3 2019 and has held it in 14 quarters since.
  • IFP Advisors's Coherus Oncology position peaked at $16K in Q4 2022.
  • 146 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.